

RESEARCH COMMUNICATION

Association of GSTM1 and GSTT1 Gene Deletions with Risk of Head and Neck Cancer in Pakistan : A Case Control Study

M Nosheen, M Ishrat, FA Malik, RM Baig, MA Kayani*

Abstract

Polymorphic deletions of GSTM1 and GSTT1 genes involved in the detoxification of potentially carcinogenic agents may be risk factors for various cancers, including head and neck cancer (HNC). In the present case-control study we aimed to access possible associations of HNC with GSTM1 and GSTT1 null genotypes in a Pakistani population. DNA was extracted from leukocytes of 388 cancer patients and 150 healthy controls by phenol-chloroform procedure. GSTM1 and GSTT1 deletion variants were genotyped by multiplex PCR assay with CYP1A1 as an internal control and further analyzed by primer specific PCR assay and sequencing. Mean age of cases and controls was 48 (+16.6) years with a male to female ratio of 1:1. Cancer of the oral cavity (57%) was most prevalent in the sampled population followed by pharynx and larynx (30% and 13% respectively). A statistically significant ($P < 0.05$) association was observed for both null genotypes in contribution to HNC as compared with the controls. The odds ratio (OR) for the GSTM1 null genotype was 2.3 with a 95% CI of 1.5-5.5 and for GSTT1 OR was 2.04 with 95% CI of 1.3-3.1. These results suggest that the GSTM1 and GSTT1 null genotypes are risk factors for HNC development among the Pakistani population.

Keywords: Head and neck cancer - GSTM1 - GSTT1 - gene deletions - Pakistani population - risk factor

Asian Pacific J Cancer Prev, **11**, 881-885

Introduction

Incidence of HNC has increased significantly worldwide in the last 20 years (Toefil et al., 2007) and is now the fifth most common cancer worldwide (Jun et al., 2010). In Pakistan, rising incidence of HNC is observed in last few years and is ranked as second most prevalent cancer. Head and neck cancer includes the cancers of the oral cavity, pharynx and larynx. Cancer of oral cavity is common, followed by larynx and pharynx (Bhurgrri et al., 2006). Its multifactorial etiology includes genetic susceptibility as well as environmental risk factors. Recent evidence indicates that carcinogen metabolizing genes play critical role in determining individual susceptibility to cancer (Patrick et al., 2009).

Carcinogens are detoxified by phase II enzymes, such as glutathione S-transferases (GSTs) which are involved in detoxification of polycyclic aromatic hydrocarbons (PAHs) and benzo (a) pyrene (Schneider et al., 2004). GSTs are family of dimeric protein enzymes known to play an important role in the Phase II detoxification of several carcinogens (Hayes and Pulford, 1995). GSTs catalyze the conjugation reactions between glutathione and carcinogen substrates and facilitate its excretion. Evidence suggests that genetic polymorphisms of these genes might increase individual susceptibility to HNC. Number of published studies have focused on GSTM1 and GSTT1

genetic variation with respect to HNC and have yielded conflicting results (Toru et al., 2008). Whether GSTM1 or GSTT1 polymorphism is a risk factor for HNC remains largely uncertain.

GSTM1 and GSTT1 are known to exhibit deletion polymorphisms (Egan et al., 2004). Persons with homozygous deletions of either the GSTM1 or the GSTT1 gene have no enzymatic functional activity of the respective enzyme and are known as null gene (Egan et al., 2004). This has been confirmed by phenotype assays that have demonstrated 94 percent or greater concordance between phenotype and genotype (Zhong et al., 1991; Warholm et al., 1995; Bruhn et al., 1998). The GSTM1 gene is located on chromosome 1p13.3 (Rossini et al., 2007) and is involved in detoxification of 7, 8-diol-9, 10-epoxide. Three variant alleles have been identified at the GSTM1 gene, one deletion allele and two others (GSTM1a and GSTM1b) that differ by C→G substitution at base position 534 (Rebbeck et al., 1997; Hengstler et al., 1998). Normal and malignant squamous cells of the larynx have been shown to express the GSTM isoform in the highest concentration compared with GSTT (Bongers et al., 1995).

GSTT1 gene is located on chromosome 22q11.23 (Rossini et al., 2007) and is involved in epoxybutanes and ethylene oxide detoxification. Two alleles have been identified at the GSTT1 locus - one functional and

the other nonfunctional (Pemble et al., 1994). GSTT1 has both detoxification and activation roles (Hayes and Pulford, 1995, Landi, 2000). GSTT1 null genotype has been reported in many studies however, fewer studies have reported any significant GSTT1 null genotype association with HNC (Geisler and Olshan, 2001; Toru et al., 2008).

The present study is designed to find out the GSTM1 and GSTT1 deletions in Pakistani population having head and neck cancer as well as normal healthy controls.

Materials and Methods

Identification of patients and normal controls

The present case-control study consisted of 388 cases with pathologically confirmed head and neck cancer along with age and sex matched 150 cancer free normal individuals as controls. They were recruited from National Oncology and Radiotherapy Institute (NORI) and Pakistan Institute of Medical Sciences (PIMS), Islamabad from March 2008 to September 2009 with a prior approval from Ethical Committees of both university and hospitals.

All patients and normal individuals participated on a volunteer basis. All subjects were personally interviewed according to a structured questionnaire. Blood was collected from subjects with their informed consent. Subjects' blood was sampled before starting the therapy.

Blood samples were collected in EDTA-containing tubes and stored at -20 °C until further use. DNA was isolated, using organic method with phenol-chloroform extraction as previously described (Vierhapper, 2004). The isolated DNA was electrophoresised on 1% ethidium-bromide stained agarose gel. Electrophoresis results were analyzed in gel documentation system (BioDocAnalyze Biometra) and photographed. 5ng dilutions were made of each DNA isolated and stored at 4°C until use.

Primer designing and multiplex PCR

Primers for all exons of GSTM1, GSTT1 and CYP1A1 (7th exon as internal control) were synthesized by using primer 3 input software version 0.4.0 (Table 1) and BLAST using NCBI PRIMER BLAST. A multiplex PCR was performed. 2µl DNA (10 ng/µl) was added to a 20µl PCR mixture composed of 2µl PCR buffer, 2µl of each primer (10mM), 0.24µl deoxynucleotide triphosphate (25mM) and 0.2µl Taq polymerase (5u/µl). The reaction mixture was placed on a 9700 thermal of ABI systems for 5min at 94°C and then subjected to 30 cycles at 94°C for 25sec, annealing temperature for 1min and 72°C for 1 min, followed by a final step at 72°C for 10min and hold at 4°C.

Amplification products were resolved on a 2% ethidium bromide-stained agarose gel along with 100bp DNA ladder (Figure 2). The photographs of gel electrophoresis were read by two technicians blind to each other's assessments. DNA samples showing amplification for CYP1A1 but not for any exon of GSTM1 and GSTT1 were considered as deleted GSTM1 and GSTT1 genotype respectively.

Technique for deletion detection

For deletion confirmation, forward and reverse primers were designed from intronic sequence before GSTM1

gene exon 1 (M1F and M1R respectively) and after last exon (M2F and M2R). For GSTT1, intronic sequence before exon 1 and after last exon was used for forward and reverse primer designing (T1F, T1R, T2F and T2R respectively). Primers for deletion confirmation were designed by same method as described above. Primer set of CYP1A1 gene was used as internal control.

The study subjects not showing any amplification with GSTM1 and GSTT1 exon specific primers were amplified with specific deletion confirmation primers (Table 1). Deleted genotype samples for GSTM1 were first amplified with M1F, M1R and also with M2F, M2R primers. They all amplified confirming the presence of intronic regions before and after the GSTM1 gene. Then the M1F and M2R primers were used to check GSTM1 deletion. Similarly for deleted GSTT1 gene T1F, T1R and T2F, T2R primers were used for deleted samples amplification. Then T1F and T2R primers were used to obtain a PCR product. All the amplified PCR products were sequenced from MacroGen

Table 1. Primers Sequences Used for GSTM1, GSTT1

Gene	Primer Sequence
GSTM1	
1 F	GCGGGAGGAAGTCTTACTGA
1 R	ACACCCCAACACACACAC
2 F	GCTTCCCTGGTGCAGACA
2 R	GCAGAGGCAGCCACAGGT
3 F	TCCACCTGTCTCAGGGATCT
3 R	TAAGCTGGGGAGAGGAGATG
4 R	CATGTGACAGTATTCTTATTTTCAGTCC
4 R	ACTCAATCTCAGCATCACAGC
5 F	GCAAGCACAACTGTGTGAG
5 R	TGTGCAGGAATGCAAGAGTC
6 F	AGTTCCAGCTTGGGGAAGAT
6 R	CCAAGAATATGTGGGCTGGA
7 F	ATGGTTTGCAGGAAACAAGG
7 R	TCCAGGACTGGGAAAACATC
8 F	GTGTCTGCAGTGGGGTTGT
8 R	AGTCCCTTGAAGAGGCAGT
GSTT1	
1 F	CCCGCAATTGGACTAAAGAG
1 R	CTCCAAACCAGACCAGCAAT
2 F	GCAGACTGGTGGGAAGAGA
2 R	TGCCTCTGAAGACTTTAGTTTCCT
3 F	CAGAGCGAGACTCCGTATCA
3 R	CAATTTGGCACAACAGAGGA
4 F	GCGAGAGAGCAAGACTCAG
4 R	GGCAGCATAAGCAGGACTTC
5 F	ATCTGTGGTCCCCAAATCAG
5 R	GGGGGTTGTCTTTTGCATAG
CYP1A1	
7 F	TGTCTACCTGGTCTGGTTGG
7 R	CCTCCAGGACAGCAATAAGG
Deletion	
M1F	CGTTAGGATCTGGCTGGTGT
M1R	GGGGCTGCACTCAGTAAGAC
M2F	CCTGGATGTCCCATTTCATC
M2R	AGATTGGGTCTGGAGACCT
T1F	GGCTGACACACTTTTCAGTGG
T1R	AGTGCCATCTATCGCATTCC
T2F	GGGGGTTGTCTTTTGCATAG
T2R	CCCAGGCTGGAGTGCAGTGG

Numbers are exons; F, forward; R, reverse

(Korea). Forward primer was used for sequencing. The sequenced results were analyzed using BioEdit v 7.0.5 software. Statistical analysis, for calculating OR, CI and standard deviation, was done by using SPSS statistics 17.0 software and GraphPad Prism 5.

Results

The study comprised of a total of 538 subjects with 388 confirmed HNC cases and 150 normal healthy controls. Male to female ratio was 1:1, this means that both the sexes were equally exposed to HNC. The mean age of head and neck cancer patients was 48 (+16.59) years and normal control was 46 (+17.69). Most prevalent area of cancer in HNC patients was oral cavity (57%), followed by Pharynx (30%) and larynx (13%).

It was found after PCR analysis that 70 patients out of 388 had *GSTM1* deletion genotype (Figure 1) which is significantly higher as compared with the controls ($P < 0.05$). The odds ratio for *GSTM1* null genotype in HNC patients compared with the controls was 2.3 with 95% CI of 1.5-5.5. Patients showing *GSTM1* deletion had mean age of 49 (+12.5) years. 50% patients showing *GSTM1* deletion genotype have cancer of oral cavity, 45% have cancer of pharynx and 5% have cancer of larynx.

Similarly 110 HNC patients had *GSTT1* gene deletion (Figure 1). *GSTT1* deletion genotype was found significantly higher ($P < 0.05$) in patients compared to controls. The odds ratio for *GSTT1* gene deletion compared to controls was 2.04 with 95% CI of 1.3-3.1. The frequency of *GSTT1* deleted genotype was 57 among oral cancer, 40 among pharyngeal cancer and 13 among laryngeal cancer patients. Sixteen patients showed deletion

of both genes and their mean age was 47 (+9.7) years. The mean age of patients with *GSTT1* deletion was 45 (+11.4) years.

GSTM1 deletion was observed in 12 controls with a mean age of 46 (+13.4) years, whereas 28 controls showed *GSTT1* deletion genotype with a mean age of 44 (+13.8) years.

To further confirm *GSTM1* and *GSTT1* gene deletions, PCR product of gene deletion primers were sequenced. The sequencing results of *GSTM1* gene revealed an amplified region 98 bp before *GSTM1* gene and a region 293 bp after the gene. This indicates that the middle portion containing *GSTM1* gene is deleted and the intronic regions are present. The portion of nearly 6 Kbp containing the entire *GSTM1* gene is deleted (Figure 1).

Similarly for *GSTT1* gene the intronic regions are present but the gene is deleted. The amplified sequence for *GSTT1* deleted gene, using intronic sequences, revealed the location of deleted region as 537 bp before the *GSTT1* gene and 333 bp after the gene. The total size of *GSTT1* deleted gene, along with some intronic portion, is approx. 9 Kbp. These results are presented in Figure 2.

Discussion

The association of *GSTM1* and *GSTT1* null genotypes with HNC risk was studied in this case- control study. Null genotypes were observed for both *GSTM1* and *GSTT1* gene. The frequency of these genotypes was significantly higher ($P < 0.05$) as compared to the controls.

GSTM1 gene is deleted in many populations with head and neck cancer (Stacy and Andrew, 2001; Toru et al., 2008). A population-based study conducted among the Chinese and Korean reported a frequency of nearly 50% for the *GSTM1* deletion genotype (Kim et al., 2000; Park et al., 2000; Setiwan et al., 2000). *GSTM1* deletion genotype varies by ethnic group among African, Asian, Hispanic, European (Rebbeck et al., 1999; Cotton et al., 2000), Caucasians (Gertig et al., 1998; Chen et al., 1999; Crump et al., 2000), French (Stucker et al., 1999) and Asians (Stacy and Andrew, 2001). The present case control study found that *GSTM1* null genotype is associated with increased risk of HNC (Trizna et al., 1995; Kihara et al., 1997; Jourenkova et al., 1998; Cheng et al., 1999; Nazar et al., 1999). Resultant loss of enzymatic activity due to *GSTM1* gene deletion has also been reported in different populations (Zheng et al., 1993; Hayes et al., 1995; Rebbeck, 1997).

In this study a significant number of HNC patients with *GSTT1* deletion genotype have been found when compared with the controls. Similar results, regarding *GSTM1* and *GSTT1* gene deletions, found in Pakistani population has also been reported in different populations such as, Americans (Gertig et al., 1998; Rebbeck et al., 1999; Cotton et al., 2000; Crump et al., 2000), Italians (Salagovic et al., 1999; Palli et al., 2000), Caucasians, Black Brazilians of South America and Amazonian Brazilians (Arodha et al., 1998). Asian populations are reported to have the highest *GSTT1* deletion genotype. In one study 58 percent of Chinese and 38 percent of Malaysians had this *GSTT1* null genotype (Lee et




Figure 1. Sequencing Results for the *GSTM1* Gene. Forward and Reverse Primers From intronic Portions Before and After the Gene. Shows Nearly 6kb Deletion has the Whole *GSTM1* Gene




Figure 2. Sequencing Results for the *GSTT1* Gene. Forward and Reverse Primers from Intronic Portions Before and After the Gene. Shows Nearly 9kb Deletion has the Whole *GSTT1* Gene

al., 1995). These GSTT1 deletions are reported to be associated with laryngeal cancer risk in addition to HNC (Trizna et al., 1997; Jourenkova et al., 1998; Cheng et al., 1999).

Although variant alleles for GSTM1 and GSTT1 have been described in literature, but the gene deletion seems to be related to disease susceptibility. Presence of null genotypes for GSTM1 and GSTT1 has been reported in different populations in both cancer individuals and cancer free controls. Statistically significant difference in gene deletions may contribute to disease susceptibility. In this study, cancer free Pakistani population is also reported to have GSTM1 and GSTT1 null genotype, and the percentage of individuals with GSTM1 and GSTT1 null genotypes are reported to be 23% and 45% (Rehan et al., 2010) similar to other populations in Singapore (Stacy and Andrew, 2000; Toefil et al., 2007) (Lee et al., 1995; Zhao et al., 1995), Turkey (Ada et al., 2004), Italy (D'Alo et al., 2004), Poland (Kargas et al. 2003), China (Setiawan et al. 2000) and in Japan (Naoe et al. 2000). Indians also have higher frequency of GSTM1 and GSTT1 deletion genotype (Mishra et al., 2004; Naveen et al., 2004; Singh et al., 2009). In conclusion the GSTM1 and GSTT1 genes have different deletion frequencies with respect to populations. The current study focuses on two genes involved in head and neck cancer incidence, and shows that individuals with GSTM1 and GSTT1 gene deletions are at an increased risk of developing head and neck cancer in Pakistani population.

Acknowledgments

We would like to acknowledge all the patients and normal individuals who have contributed in this study. Thanks to COMSATS Institute of Information and Technology, Islamabad for research lab and equipments. The authors also acknowledge the financial support of Higher Education Commission, Islamabad (Pakistan) There is no conflict of interest.

References

Ada AO, Süzen SH, Iscan M (2004). Polymorphisms of cytochrome P450 1A1, glutathione S-transferase M1 and T1 in a Turkish population. *Toxicol Lett*, **151**, 311-5.

Arruda VR, Grignolli CE, Gonçalves MS, et al (1998). Prevalence of homozygosity for the deleted alleles of glutathione S-transferase mu (GSTM1) and theta (GSTT1) among distinct ethnic groups from Brazil, relevance to environmental carcinogenesis. *Clin Genet*, **54**, 210-4.

Bhurgri Y, Bhurgri A, Usman A, et al (2006). Epidemiological review of head and neck cancers in Karachi. *Asia Pac J cancer prev*, **7**, 195-200.

Bongers V, Snow GB, Braakhuis BJ (1995). The role of glutathione S-transferases in head and neck squamous cell carcinogenesis. *Eur J Cancer B Oral Oncol*, **31**, 349-54.

Bruhn C, Brockmoller J, Kerb R, et al (1998). Concordance between enzyme activity and genotype of glutathione S-transferase theta (GSTT1). *Biochem Pharmacol*, **56**, 1189-93.

Chen C, Madeleine MM, Weiss NS, et al (1999). Glutathione S-transferase M1 genotypes and the risk of vulvar cancer, a population-based case-control study. *Am J Epidemiol*, **150**, 437-42.

Cheng L, Sturgis EM, Eicher SA, et al (1999). Glutathione S-transferase polymorphisms and risk of squamous cell carcinoma of the head and neck. *Int J Cancer*, **84**, 220-4.

Cotton S, Sharp L, Little J, et al (2000). Glutathione S-transferase polymorphisms and colorectal cancer. HuGE review. *Am J Epidemiol*, **151**, 7-32.

Crump C, Chen C, Appelbaum F (2000). Glutathione S-transferase theta 1 gene deletion and risk of acute myeloid leukemia. *Cancer Epidemiol Bio Prev*, **9**, 457-60.

D'Alo F, Voso MT, Guidi F, et al (2004). Polymorphism of CYP1A1 and glutathione S transferase and susceptibility to adult acute myeloid leukemia. *Haematologica*, **89**, 664-70.

Egan KM, Cai Q, Shu XO, et al (2004). Genetic polymorphisms in GSTM1, GSTP1 and GSTT1 and the risk for breast cancer, results from Shanghai breast cancer study and meta analysis. *Cancer Epidemiol Bio Prev*, **13**, 197-204.

Geisler SA, Olshan AF (2001). GSTM1, GSTT1 and the risk of squamous cell carcinoma of head and neck, a mini huge review. *Am J Epidemiol*, **154**, 95-105.

Gertig D, Stampfer M, Haiman C (1998). Glutathione S-transferase GSTM1 and GSTT1 polymorphisms and colorectal cancer risk, a prospective study. *Cancer Epidemiol Bio Prev*, **7**, 1001-5.

Hayes JD, Pulford DJ (1995). The glutathione S-transferase supergene family, regulation of GST and the contribution of isoenzymes to cancer chemoprevention and drug resistance. *Crit Rev Biochem Mol Biol*, **30**, 445-600.

Hengstler J, Arand M, Herrero ME, et al (1998). Polymorphisms of N-acetyltransferases, glutathione S-transferases, microsomal epoxide hydrolase and sulfo transferases, influence on cancer susceptibility. *Recent Results Cancer Res*, **154**, 46-85.

Jourenkova N, Reimikainen M, Bouchardy C, et al (1998). Larynx cancer risk in relation to glutathione S-transferase M1 and T1 genotypes and tobacco smoking. *Cancer Epidemiol Bio Prev*, **7**, 19-23.

Jun T, Ming Y, Xin N, et al (2010). Genetic polymorphisms in cytochrome P450 genes are associated with an increased risk of squamous cell carcinoma of the larynx and hypopharynx in a Chinese population. *Cancer Genet Cytogenet*, **196**, 76-82.

Kargas C, Krupa R, Walter Z (2003). Combined genotype analysis of GSTM1 and GSTT1 polymorphism in a polish population. *Hum Biol*, **75**, 301-7.

Kihara M, Kubota A, Furukawa M, et al (1997). GSTM1 gene polymorphism as a possible marker for susceptibility to head and neck cancers among Japanese smokers. *Cancer Lett*, **112**, 257-62.

Kim WJ, Lee HL, Lee SC, et al (2000). Polymorphisms of Nacetyltransferase2, glutathione S-transferase mu and theta genes as risk factors of bladder cancer in relation to asthma and tuberculosis. *J Urol*, **164**, 209-13.

Landi S (2000). Mammalian class theta GST and differential susceptibility to carcinogens, a review. *Mutat Res*, **463**, 247-83.

Lee EJ, Wong JY, Yeoh PN, et al (1995). Glutathione S transferase theta (GSTT1) genetic polymorphism among Chinese, Malays and Indians in Singapore. *Pharmacology*, **5**, 332-4.

Mishra DK, Kumar A, Srivastava DS, et al (2004). Allelic variation of GSTT1 GSTM1 and GSTP1 gene in north Indian population. *Asia Pac J Cancer Prev*, **5**, 362-5.

Naoe T, Takeyama K, Yokozawa T, et al (2000). Analysis of genetic polymorphism in NQO1, GSTM1, GSTT1, and CYP3 A4 in 469 Japanese patient with therapy related leukemia myeloid plastic syndrome and denovo acute myeloid leukemia. *Clin Cancer Res*, **6**, 4091-5.

- Naveen AT, Adithan C, Padmaja N, et al (2004). Glutathione S transferase M1 and T1 null genotype distribution in south Indians. *Eur J Clin Pharmacol*, **60**, 403-6.
- Nazar VS, Vaughan T, Burt R, et al (1999). Glutathione S transferase M1 and susceptibility to nasopharyngeal carcinoma. *Cancer Epidemiol Bio Prev*, **8**, 547-51.
- Palli D, Vineis P, Russo A, et al (2000). Diet, metabolic polymorphisms and DNA adducts, the EPIC-Italy cross-sectional study. *Int J Cancer*, **87**, 444-51.
- Park SK, Yoo KY, Lee SJ, et al (2000). Alcohol consumption, glutathione S-transferase M1 and T1 genetic polymorphisms and breast cancer risk. *Pharmacogenetics*, **10**, 301-9.
- Patrick KH, Steven SC, Chad AG, et al (2009). Molecular techniques and genetic alterations in head and neck cancer. *Oral Oncol*, **45**, 335-39.
- Pemble S, Schroeder K, Spencer S, et al (1994). Human glutathione S-transferase theta (GSTT1), cDNA cloning and the characterization of a genetic polymorphism. *Biochem J*, **300**, 271-6.
- Rebbeck TR (1997). Molecular epidemiology of human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility. *Cancer Epidemiol Bio Prev*, **6**, 733-43.
- Rehan SS, Amir M, Ahmed IM, et al (2010). Frequency distribution of GSTM1 and GSTT1 Null allele in Pakistani population and risk of disease incidence. *Environ toxicol pharm*, **30**, 76-9.
- Rossini A, Rapozo DC, Soares SC, et al (2007). Polymorphism of GSTP1 and GSTT1 but not of CYP2A6, CYP2E1 or GSTM1, modify the risk of esophageal cancer in western population. *Carcinogenesis*, **28**, 2537-42.
- Salagovic J, Kalina I, Habalova V (1999). The role of human glutathione S-transferases M1 and T1 in individual susceptibility to bladder cancer. *Physiol Res*, **48**, 465-71.
- Schneider J, Bernges U, Philipp M, et al (2004). GSTM1, GSTT1, and GSTP1 polymorphism and lung cancer risk in relation to tobacco smoking. *Cancer Lett*, **208**, 65-74.
- Setiawan VW, Zhang F, Yu ZU, et al (2009). GSTT1 and GSTM1 null genotypes and risk of gastric cancer, a case-control study in a Chinese population. *Cancer Epidemiol Bio Prev*, **9**, 73-80.
- Singh S, Kumar V, Thakura S, et al (2009). Genetic polymorphism of glutathione S-transferase M1 and T1 in Delhi population of Northern India. *Environ Toxicol Phar*, **28**, 25-9.
- Stacy AG, Andrew FO (2000). GSTT1 and GSTM1, and the risk of squamous cell carcinoma of the head and neck, a mini huge review. *Amer J Epid*, **154**, 95-105.
- Stucker I, de Waziers I, Cenee S, et al (1999). GSTM1, smoking and lung cancer, a case-control study. *Int J Epidemiol*, **28**, 829-35.
- Toefil L, Oana CT, Horea AA, et al (2007). Head and neck cancer, epidemiology and histological aspects- Part 1, A decades results 1993-2003. *J Cranio Maxill Surg*, **35**, 120-5.
- Toru H, Masaharu Y, Shinji T, et al (2008). Genetic polymorphisms and head and neck cancer risk. *Int J Oncol*, **32**, 945-73.
- Trizna Z, Clayman G, Spitz M, et al (1995). Glutathione S transferase as risk factor for head and neck cancers. *Am J Surg*, **170**, 499-501.
- Vierhapper H, Bieglmayer C, Heinze G, et al (2004). Frequency of RET protooncogene mutations in patients with normal and with moderately elevated (50-100 pg/ml) pentagastrin-stimulated serum concentrations of calcitonin. *Thyroid*, **14**, 580-3.
- Warholm M, Rane A, Alexandrie A, et al (1995). Genotypic and phenotypic determination of polymorphic glutathione transferase T1 in a Swedish population. *Pharmacogenetic*, **5**, 252-4.
- Zhao B, Lee EJ, Wong JY, et al (1995). Frequency of mutant CYP1A1, NAT2 and GSTM1 alleles in normal Indians and Malays. *Pharmacogenetics*, **5**, 275-80.
- Zheng T, Boyle P, Walter WC, et al (1993). A case-control study of oral cancer in Beijing, People's Republic of China. Association with nutrient intakes, foods and food groups. *Eur J Cancer Oral Oncol*, **29**, 45-55.
- Zhong S, Howie A, Ketterer B, et al (1993). Glutathione S transferase mu locus, use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. *Carcinogenesis*, **12**, 1533-7.